ArticleNeurology and therapy2026

Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

Dawn C Buse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.